Keywords: amgen, denosumab, effective, fosamax, biotechnology, major, osteoporosis
Amgen
Article | 26 May 2008
US biotechnology major Amgen's osteoporosis drug candidate denosumab was more effective than Merck & Co's $1.7 billion-a-year Fosamax (alendronate), according to data ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
